---
document_datetime: 2023-09-21 22:25:14
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/adakveo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: adakveo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.558476
conversion_datetime: 2025-12-14 23:11:15.020846
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                             | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                     |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------|
| A20/0013             | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 26 January 2023 the opinion of the European Medicines Agency further to assessment of the results of the STAND study. The CHMP was requested to assess the impact thereof on the benefit-risk balance of Adakveo and to give its recommendation whether the marketing | 25/05/2023                                  | 03/08/2023                                     |                                  | Please refer to the assessment report: Adakveo EMEA/H/A-20/1525/C/4874/0013 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

Adakveo Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | authorisation of this product should be maintained, varied, suspended or revoked.                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |          |                                                                              |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------|
| IB/0011/G           | This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB | 13/04/2023 | 23/06/2023 | Annex II | longer authorised                                                            |
| PSUSA/10888 /202205 | Periodic Safety Update EU Single assessment - crizanlizumab                                                                                                                                                                                                                                                                                                                                                                                                                        | 01/12/2022 | n/a no     |          | PRAC Recommendation - maintenance                                            |
| IB/0010/G           | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.e.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol Medicinal product                                                                                                                                             | 06/10/2022 | n/a        |          |                                                                              |
| II/0007             | Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the results                                                                                                                                                                                                                                                                                                                                                                              | 08/09/2022 | 23/06/2023 | SmPC     | Update of section 5.2 of the SmPC to include information from PK reanalysis. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | from PK re-analysis. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                     |            |            |                       | For more information, please refer to the Summary of Product Characteristics.                                                              |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| R/0008              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                | 23/06/2022 | 12/08/2022 |                       | authorised                                                                                                                                 |
| PSUSA/10888 /202111 | Periodic Safety Update EU Single assessment - crizanlizumab                                                                                                                                                                                                                                            | 10/06/2022 | n/a        | longer                | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10888 /202105 | Periodic Safety Update EU Single assessment - crizanlizumab                                                                                                                                                                                                                                            | 02/12/2021 | n/a no     |                       | PRAC Recommendation - maintenance                                                                                                          |
| II/0005             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS product                                                                                                                                                                                                         | 21/10/2021 | n/a        |                       |                                                                                                                                            |
| R/0003              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                | 22/07/2021 | 29/09/2021 |                       |                                                                                                                                            |
| PSUSA/10888 /202011 | Periodic Safety Update EU Single assessment - crizanlizumab                                                                                                                                                                                                                                            | 24/06/2021 | 26/08/2021 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10888/202011. |
| IB/0002/G           | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.I.d.1.a.4 - Stability of AS - Change in the re-test Medicinal | 11/06/2021 | 26/08/2021 | SmPC and PL           |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->